LVW Advisors LLC Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

LVW Advisors LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 766 shares of the pharmaceutical company’s stock after selling 26 shares during the period. LVW Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $308,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in VRTX. Mutual Advisors LLC grew its stake in Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 21 shares during the last quarter. Daymark Wealth Partners LLC grew its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after purchasing an additional 22 shares during the last quarter. Grove Bank & Trust increased its stake in shares of Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after purchasing an additional 22 shares in the last quarter. Outlook Wealth Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 2.8% during the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after purchasing an additional 24 shares during the last quarter. Finally, Dunhill Financial LLC lifted its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of analyst reports. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Stifel Nicolaus upped their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday, January 13th. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:VRTX opened at $422.00 on Tuesday. The company has a market capitalization of $108.68 billion, a price-to-earnings ratio of -212.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The company has a 50 day moving average of $440.94 and a two-hundred day moving average of $466.06. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.